Study S002019

A Trial Investigating the Effect of Semaglutide on Atherosclerosis in Patients With Cardiovascular Disease and Type 2 Diabetes

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT04032197
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 101
Start: 2019-08-12
Primary completion: 2022-12-16
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG:Semaglutide; DRUG:Placebo (semaglutide)
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1215-4058; REGISTRY:2018-002289-38; NIH:2018

Registered primary outcomes

Change in maximum target-to-background ratio (TBR) for 18F-fluorodeoxyglucose (FDG) in the carotid arteries [From baseline (from 41 days before randomisation) to week 26]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0006311	Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial. James S, American heart journal	2025	Randomized trial	PMID 40345413 DOI	cites ClinicalTrials.gov:NCT04032197; registry reference DERIVED:40345413